Short Interest in PainReform Ltd. (NASDAQ:PRFX) Rises By 92.4%

PainReform Ltd. (NASDAQ:PRFX) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 194,929 shares, a growth of 92.4% from the January 15th total of 101,333 shares. Currently, 73.8% of the shares of the company are sold short. Based on an average daily trading volume, of 6,625,219 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 6,625,219 shares, the days-to-cover ratio is presently 0.0 days. Currently, 73.8% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

PainReform Stock Up 1.7%

Shares of PRFX opened at $2.96 on Friday. PainReform has a twelve month low of $2.57 and a twelve month high of $27.35. The stock has a market cap of $1.18 million, a PE ratio of 0.00 and a beta of 0.61. The business’s 50-day moving average price is $3.99 and its 200-day moving average price is $5.59.

PainReform (NASDAQ:PRFX) last released its quarterly earnings data on Wednesday, October 1st. The company reported ($2.72) EPS for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.